if you own celgene, i would almost think of selling puts as a year and a half as strategy.red to buy more later. the stock has been from the lower left to the upper right for the last year and you keep on riding, maybe you sell one month outputs. because if you're not full on your stock position, great way to add yield. >> another way to play it, given where premiums are is to sell covered calls against it. you could even, this is going to be in the subsequent edition, sell both puts and calls against the long position, buy more at lower levels and called out of your stock at higher levels and in the meantime collect maybe 4 or 5%. >> what kind of music would go with that one? >> dance the night away. >> coming up next, we're taking your tweets. stay tuned. ♪ ♪ >> we love getting tweets, let's answer a few. peter asks, how about selling puts on oil through uso? >> so the etf supposed to track wti here, this is one where there's an interesting setup as far as options prices, it can only go to zero and calls are more expensive than puts. it's a scenario where at the moment it

do it. >> celgene. >> macy's defined risk into earnings. >>> our time is expired. i'm melissa lee.t now. >> announcer: the following is a paid advertisement for the revolutionary 21 day fix, brought to you by beachbody. >> thank you! [ laughs ] hello there. i'm tom bergeron, and this show is about transforming how you look and feel, starting right now. >> announcer: are you struggling right now to lose weight? >> i've struggled with my weight my entire life. >> i really want to... lose this. >> i didn't want to walk down the aisle weighing 220 pounds. i need to do something, and it needs to happen right now. >> announcer: now there's a breakthrough new way to lose those pounds and inches, and it happens in just 21ay

so if you look, we've been fa r favoring gilead and celgene. of the market year to date. celgene has a lower risk profile when you look ahead. they've given guidance through 2020. no other biotech company that's given guidance expecting about 20, 25% eps growth per year. we like the pipeline think there's upside. great earnings k-visibility. not a lot of risk. we think that's a nice safe one for generalists to be in. the fundamentals look good and less choppy than gilead from this point onward. >> how about the other names in the space, that don't get a lot of attention but you have a buy on amgen, why? the pipeline or what is it you see right now there? >> ieyg mean for am gep for us s a combination of two things. it still is an earnings rating to the upside and earnings are still going up. decent visibility on the revenue side, like their pipeline including the similar play long-term, great cardios vascular drug that will get approved and next year data on the bone disease product. they're still expanding margins and that's key. earnings goi

. >> then i have google walmart, and celgen. >> well we have a problem. we're going to have to get rid of it. we have a tech in that spot and we have -- oh two things here. retailer in walmart and costco. get rid of walmart. we have two bio techs and get rid of amgen, we need to have a diversified industrial so i'm going to pick instead of amgen united technologies and instead of walmart what we're going to need is -- how about a little health care -- oh we have the celgene, we can't do that you know what i'm going to give you an oil because it's okay. i'm going to give you the royal dutch. that's all right because that stock is going to come in tomorrow and we're going to pick some up. wow, tough game today. that's tough. two of a kind and two of a kind. two pair that guy. stick with cramer. we needed 30 new hires for our call center. i'm spending too much time hiring and not enough time in my kitchen. [ female announcer ] need to hire fast? go to ziprecruiter.com and post your job to over 30 of the web's leading job boards with a single click; then simp

i like regeneron and celgene on the weakness. celgene has a better product profile in terms of patents. >> competing with the pharmacy benefits. >> today my charitable trust owns abbvie. the price cut was a shocker. >> came out on the call this year things will be more competitive than last year. >> holy cow. companies that you say, they don't have competition. well, they do. speaking of competition, shake shack, in terms of food with integrity, chipotle. now, this is what you need to know about chipotle. this is not the first time this has happened. do you know every one has been a buy? every one of these pull backs, no different. there was a pork issue, remember, they had humane treatment -- read the conference call, what they were doing to pigs is horrendous. understand what company chipotle is. chipotle is about putting the customer first by having food with integrity. it hurt them this quarter. you know what? >> if they have a pork shortage or beef shortage, they have to raise prices more as a result of trying to source what

now for celgene, we're talking about revlimid. that's 38% of its revenues. profile of these companies and these drugs potentially makes them vulnerable. >> i wonder why he would go after such a large company that could potentially fight off a patent charge really well unless he's going to be in short and get out as soon as the stock falls. >> i think it's an optical. you can't just prey on little guys that you can push around. i think you have to have some of the bigger guys out there to sort of protect yourself from people saying he's just taking shots against companies whose stocks he can miss. that would be my take on the whole thing. >> with this model though he's actually looking to be aggressive and actually make something happen in terms of the patent being invalidated. >> what he's doing -- >> that's not just hoping the stock trades down. that's trying to hurt the company. >> when they originally talked about this according to reports we found in the financial times and reuters, he said they're not going to settle. they're going through the patent of

i want to know about celgene. >> big rotation, in the names like eaton. that's what happens periodically. celgene has a real bad head and shoulders going. i say let it come down 5% and pull the trigger. why? because they're putting out numbers for 2020 that are going to be amazing the stock looks dirt cheap in the outyears. jared in new york, jared? >> caller: yes boo-yah, big fan, jim. thanks for having me on. >> excellent. >> caller: calling about c.r. barnes, i want to know if it's a buy, sell or hold or if you see anything with a better valuation. >> got to go to bard. it's a terrific stock. the only thing i like more than that is everett life sciences. mike mike mike in new jersey. mike. >> caller: hi, how are you. i'm mike from new jersey. big boo-yah to ya. long time listener first time caller. love your show and hope you provide to the average investor. i purchased a lot out of micron technology in 2014 at the $32 level. >> yeah. you know i think micron's part of a whole cohort of tech stocks nobody wants right now. i think the stock can work its

winners for the week on the nasdaq 100, regeneron, celgene, biogen.k in the top four. >> yeah. facebook, facebook basically, you know people reval waiting, it's a rerating of the company. regeneron had head-to-head competition that they won. celgene had expanded use of the multiple don't forget biogen the alzheimer's product which i think will take the world by storm. the big four copming on strong. >> bob pisani, see what's move on the floor. >> mixed morning. mixed morning in europe. flash pmi data either side of positive or negative. france better than expected. take a look at europe. again, still not a lot of big movements. i'm sure you saw the greek finance minister on the air, seems confident they'll get a section-month extension. i agree with jim, the deal is muddled through, debt extented into infinity but it's not removed or erased. no haircut. austerity relaxed and everybody makes a deal. alternative, we do not know how much contagion there might be to the eurozone as a whole and the european banking system if greek defaults or leaves the eu

celgene is a good story technically. it's lagged the ivb by a touch here.k it has the prospects of hitting the levels it's talking about. >> of course it does. it was trading at 114 friday. this is the thing about selling puts. i think about it differently. if you own it, i would think of selling puts as maybe a yield enhancing strategy if you're prepared to buy more later. if you're going to keep riding this stock, maybe you sell one month out puts at a level you would buy more because if you're not full up on your stock positions, this is a great way to add yield. >> if you own the stock already, another way to play it, given where premiums are, you could even -- this is going to be in the subsequent edition -- sell both puts and calls against, buy more at lower levels, you'll be called out of your stock at higher levels and in the meantime you could collect probably 4%, maybe 5%. >> what kind of music goes with that one? >> "dance the night away." >>> coming up next, we are taking your tweets. stay tuned. >>> we love getting tweets. let's answer a few. p

today some of the gainers that are lifting the nasdaq include celgene which had a cancer drug approvede the stocks that continue to move things higher. you can't talk about the nasdaq's return to 5,000 without talking about apple. apple continues to make new highs today. it is just off of that today. but what's interesting is, when you think about where the leadership is going to be, you know, it was a little more than 100 years ago we had the big three automakers. these could be the big 3 starting in the 2020s or 2030s. >> eight days in a row is good but in 199 nasdaq had -- 1979 nasdaq had 19 straight up days. >> that is good. >> let's get back to headquarters and wapner and the half. ♪ >>> welcome to the halftime show. meet our starting lineup. stephen weiss the managing partner of short hills capital josh browne, ceo of ritholtz management and jon and pete are the co-founders of ohm and mario is the founder of gamco investors. our game plan, $33 billion, that's what someone says instagram is worth. which has us wondering if people e

i still prefer celgene. frank in ohio, frank? frank?: jim, thanks for your help with understanding the daily market swing. >> thank you. that's what i'm out to hear to explain what is occurring. what's going on? >> caller: okay, my stock is baxter international. >> baxter needs to split up. i suggest they do that. that's one dog stock. it has lost the faithful. it used to be the three bs. i don't mean beethoven, bach and brahms. mike in new jersey mike mike mike? >> caller: i'll give you a bbb boo-yah. what's happening? >> talented boo-yah. what's going on with you, sir? >> caller: long-time fiscal holder of food distributor, not because of the merger coming up. what do you think long-term? >> if they can get that merger through, and that stock goes to 50th, if they don't, it's going to hold right here. that merger does matter a great deal. i need to go to laurie in florida. laurie? >> caller: jim boo-yah. greetings from ft. lauderdale. >> hey how is it going? >> caller: great. i'm calling about sirius satellite radio. >> i like sirius.

purchasing those biotechs that do have no competition to speak of and big numbers in the out years, celgene and regeneron. again, when you see a stock down badly like gilead or abvye, there's a second day of pain coming as the sellers willing to dump those stocks down 4% 5% 6%, they'll be back tomorrow. they're not done. that's how it works. more losses ahead. that's just what the -- and that's angry dissolution portfolio managers who can't take the pain anymore. they will sell gilead and abvye because they can't take that address. how about the slaughter in the oils? now, we know the price of oil ran up too much in one week a 19% gain a bull market in a week. a bull market in a barrel! unsustainable, pretty much any commodity. so we're due for a kind of decline that we had. it was pretty vicious, though. we know from the brilliant ceo of kinder morgan that oil may be too cheap in the low 40s. put yourself in the shoes of potential buyers. they know there's voracious demand which held on january 28th. they'll try to buy oil around 45, that's about $3.50 below where oil went out today. remem

now you've got amgen, celgene, gilead have earnings, pipelines and bigger pipelines behind them. >> onehing going on right now that perhaps, you know, we didn't have back in 2000. for better or worse very a guy named bill dudley now. coming up on the one-year anniversary when dudley talked down these better biotechs companies but yet he still came out in march of last year and said biotechs are looking overvalued. small to mid cap social media overvalued. is that going to happen again if the nasdaq keeps going? i'm looking for some of the stocks to get dudley'ed. >> maybe one of the biggest buying opportunities when the fed in some sort of survey or report or whoever put it together suggested that there was froth in that part of the market. >> that might be the biggest legacy of the nasdaq 5,000 in the first time. we're conditioned to look for this mania out there. the only i would caution you don't have to have a mania to have a market problem the fed is not trying to market time. alan greenspan's speech was in 1996. >> yeah, right, four years after that. >> four years of green snooeld

and that's a record high for celgene. o move to another one, of course what's happening with retail. home depot up 5%. it's a big deal. we're in the spring selling season, these guys could get a bump as people go to buy lawn mowers. and then one more industrials. it's a little bit more volatile in terms of the aircraft industry, but still boeing shares are up about 14% year to date. what it comes down to is yes there are signs that the bull market is intact. some of these record highs are an example of it but it doesn't take away from the fact that despite the record highs, because of greece we have some ideas that maybe this market is at least for now waiting and seeing. back over to you. >> yeah. thanks, dom, for running through the names. is it a good sign so many stocks are hitting all-time highs or are investors getting overexcited? joining us is tom lee. i would take it you say this is a good thing that some of the individual stories, the earnings fundamentals are taking a front seat to these crazy headlines and vol

relationship with pharma ci -- think the cancer franchise is something that j&zwrchltj does covet to block celgenek's moved up too much. >> even up too much to account for potential premium that a buyer would pay? >> i think so. the stock's moved up too much to do the deal. that's a stock that can cool auch. off. i think gorsky's got what he needs from the partnership. potbelly had momentary mojo and the cfo leaves. when a cfo leaves particularly that one often thought of as the master -- >> going to a competitor, by the way. >> mast somewhere commander of got bell potbelly. giving back. i prefer denny's. i prefer honestly i've got popeye's on tonight. that was killed. >> what else? >> two stocks. blackhawk was horrendous, yet i think that bill tauscher has to explain what happened to revenues. that's a great story. the company that does cards, the wall of cards. er. there's answers that have to happen. they may turn out to be opportunities. >> as we close out february there's a point you want to sell discretionary and buying utilities? am i wrong? is that day coming. >> somebody upgraded i don't

celgene gave up a lot of the gains in a short amount of time last week on patent concerns. >> it happenseriodically. the shorts run with it for a while. gilead hurt by the price wars and hep c, regeneron recommended today, regeneron has fewer problems but they're in a war with amgen. that group has not led us. it's semis. by the way, software hasn't led us. microsoft a big disappoint. apple is important. >> but tesla hasn't. >> no. oh bringing that up huh? funny, i checked into twitter a few times this weekend and it's -- i almost, you know, it's like you're in i street fight sometimes. i want to come to your aid but i can't figure out how to get involved. >> those guys cam with a gun and i came with chemical nuclear weapons the gun thing, a knife i'm have tactical nukes and things people haven't seen and haven't been tested. >> active over the weekend. >> i was active. >> they come to us cramer blocked me can you help? >> my instinct get in there as it would be, of course but glad you're handling it. >> i have a good time on twitter. >> you don't need help. >> guys that don't like it? y

. >> going to gilead celgene -- >> no. it's done. did you hear what happened. >> gilead and abbvie?> no i said disney's blockbuster blockbuster. the day of the blockbuster biotech ended with the price cut. >> from lipitor to "frozen." >> will ferrell, i love that man. impressed watched will ferrell do the lip sync. >> i haven't seen it. >> kevin hart's good too. very funny. >> when we come back news involving twitter ahead of tomorrow's exclusive with the ceo, dick costolo, 9:00 a.m. shares of cigna, tripped since the ceo in '09. get his perspective on the anthem hack attack. haven't gotten to retail. ralph lauren esty, under armour armour, more "squawk on the street" in a moment. can data help cure a disease? the right treatment for you is out there. the problem is some of it's in this lab. some of it is in her head. some of it's in this new journal. and the rest of it is in your personal medical history. ibm watson can not only read this data, but understand it. it's trained by doctors. and it's always learning. it can help find hidden correlations and help your doctor recommend t

i'm not concerned about gilead ten times earnings or celgene 26 or biogen at 23 because they've got greatrtfolio. i don't like acquiring to grow but i don't have any holes. >> that's the strategy they're pursuing at these companies they've been rewarded for it dramatically. valeant, 200. actavis never looked back since they announced the deal. >> allergen's a good company. i'm worried about -- this is where i'm worried but i can't poke holes. tell me where i'm wrong that actavis is bad. i don't see it. >> believe me you're going to fine few people who will. >> we'll look back and say, one of these companies, i'm not going to mepgntion, one will, i called foul on tesla the other day. i have to get a tesla so i don't look for a bomb in the trunk in the back. there's no trunk. >> model-s, best model overall in consumer reports for the second consecutive year. >> model-s per share fabulous. press release per share amazing. miles per gallon amazing per share. earnings per share not as good. >> pep >>perage farm. >> sent me salad dressing other day. i was complaining if you went to campbell's s

celgene in six months up 35%. gilead up 25. biogen up 18. is she going to double down?he small stocks. >> i know. >> it wasn't her. some person on the staff. i don't know. >> which is the one she didn't like? isis. >> bizarre -- it wasn't in the statement. it was addendum. >> i feel awful, i think she's so good. >> you do? >> yeah. i just this she's early on the call. about like 17 years early. want to come back to a couple of movers from yesterday. valeant, up 15%. down a bit today. >> go buy it. stop it. that guy, i mean i got a lot of heat saying good things -- >> your interview so great. i was e-mailing david, i'm not getting that call, or on the call, but i was e-mailing, i'm listing to the interview. i keep thinking there's holes in the story it's a rollup it's a rollup, and i listened to the interview. gosh, darn this guy is real. >> i know. we have been through areas where there are other ceos that were embraced what for rollups, swv said he just knows how to do it differently. in fact that was not the case. you wonder i mean how is it that you can take old prod